­
­
­
­

Inventi Impact: Preventive & Social Medicines

Articles

  • Inventi:hpsm/42839/21
    HIV Drug Resistance Mutations Detection by Next-Generation Sequencing During Antiretroviral Therapy Interruption in China
    01-Jul-2021 Research 2021 : July - September
    Miaomiao Li, Shujia Liang, Chao Zhou, Min Chen, Shu Liang, Chunhua Liu, Zhongbao Zuo, Lei Liu, Yi Feng, Chang Song, Hui Xing, Yuhua Ruan, Yiming Shao, Lingjie Liao

    Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority drug resistance variant. A cross-sectional study was conducted in patients with ART interruption in five regions in China in 2016. Through Sanger and next-generation sequencing in parallel, HIV drug resistance was genotyped on their plasma samples. Rates of HIV drug resistance were compared by the McNemar tests. In total, 174 patients were included in this study, with a median 12 (interquartile range (IQR), 6–24) months of ART interruption. Most (86.2%) of them had received efavirenz (EFV)/nevirapine (NVP)-based first-line therapy for a median 16 (IQR, 7–26) months before ART interruption. Sixty-one (35.1%) patients had CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC and 35 (20.1%) CRF01_AE. Thirty-four (19.5%) of the 174 patients were detected to harbor HIV............

    How to Cite this Article
    Attribution/ CC Compliant Citation: Li, Miaomiao, et al. "HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China." Pathogens 10.3 (2021): 264. https://doi.org/10.3390/pathogens10030264 http://creativecommons.org/licenses/by/4.0/ Some formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text